Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy

被引：18

作者：

Shuai, Yanjie ^{[1
]}

Ma, Li ^{[1
]}

机构：

[1] Hebei Med Univ, Affiliated Hosp 4, Hebei Prov Tumor Hosp, Shijiazhuang, Hebei, Peoples R China

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2019年 / 215卷 / 01期

关键词：

Neoadjuvant chemotherapy; Estrogen receptor; Progesterone receptor; Human epidermal growth factor receptor 2; Ki67; Pathologic complete response; Prognosis; HORMONE-RECEPTOR STATUS; PRIMARY SYSTEMIC THERAPY; CORE NEEDLE-BIOPSY; NODE METASTASES; OPEN-LABEL; TRASTUZUMAB; TUMOR; SURVIVAL; MULTICENTER; DOXORUBICIN;

D O I：

10.1016/j.prp.2018.11.003

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Neoadjuvant chemotherapy(NCT) has become the standard treatment for breast cancer. The information about the tumor's sensitivity to chemotherapy and prognostic significance based on response to therapy can be provided after individualized neoadjuvant treatment The biomarkers are key factors in the decision-making process regarding treatment as well as important prognostic indicators. Studies have shown that patients who achieve pathological complete response(pCR) after NCT have a better prognosis. For patients who do not achieve pCR, the pathological characteristics of the residual tumor can make an effect on the survival. Furthermore, the immunohistochemical (IHC) markers of the residual diseases after primary systemic therapy might be different from the primary tumor. Estrogen receptor (ER), progesterone receptor (PR), and Ki67 can usually change after NCT, while human epidermal growth factor receptor 2(HER2) seems to be more stable. The relationship between changes in breast cancer molecular biomarkers and the prognosis after neoadjuvant therapy is not yet clear. The article will make a review about it.

引用

页码：29 / 33

页数：5

共 43 条

[11] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia Valeria ;

Magazzu, Domenico ;

McNally, Virginia ;

Douthwaite, Hannah ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2016, 17 (06) :791-800

[12] Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Lluch, Ana ;

Tjulandin, Sergei ;

Zambetti, Milvia ;

Moliterni, Angela ;

Vazquez, Federico ;

Byakhov, Mikhail J. ;

Lichinitser, Mikhail ;

Climent, Miguel Angel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Magazzu, Domenico ;

Heinzmann, Dominik ;

Steinseifer, Jutta ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (06) :640-647

[13] Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy [J].

Gonzalez-Angulo, AM ;

McGuire, SE ;

Buchholz, TA ;

Tucker, SL ;

Kuerer, HM ;

Rouzier, R ;

Kau, SW ;

Huang, EH ;

Morandi, P ;

Ocana, A ;

Cristofanilli, M ;

Valero, V ;

Buzdar, AU ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7098-7104

[14] Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change [J].

Hariri, Nosaibah ;

Roma, Andres A. ;

Hasteh, Farnaz ;

Walavalkar, Vighnesh ;

Fadare, Oluwole .

ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 31 :14-19

[15] Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy [J].

Hennessy, BT ;

Hortobagyi, GN ;

Rouzier, R ;

Kuerer, H ;

Sneige, N ;

Buzdar, AU ;

Kau, SW ;

Fornage, B ;

Sahin, A ;

Broglio, K ;

Singletary, SE ;

Valero, V .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9304-9311

[16] Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer [J].

Hirata, T. ;

Shimizu, C. ;

Yonemori, K. ;

Hirakawa, A. ;

Kouno, T. ;

Tamura, K. ;

Ando, M. ;

Katsumata, N. ;

Fujiwara, Y. .

BRITISH JOURNAL OF CANCER, 2009, 101 (09) :1529-1536

[17] Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer [J].

Hurley, J ;

Doliny, P ;

Reis, I ;

Silva, O ;

Gomez-Fernandez, C ;

Velez, P ;

Pauletti, G ;

Pegram, MD ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) :1831-1838

[18]

Jin GC, 2015, INT J CLIN EXP PATHO, V8, P914

[19] Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study [J].

Jin, Xi ;

Jiang, Yi-Zhou ;

Chen, Sheng ;

Yu, Ke-Da ;

Shao, Zhi-Ming ;

Di, Gen-Hong .

ONCOTARGET, 2015, 6 (11) :9600-9611

[20] Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [J].

Kuerer, HM ;

Newman, LA ;

Smith, TL ;

Ames, FC ;

Hunt, KK ;

Dhingra, K ;

Theriault, RL ;

Singh, G ;

Binkley, SM ;

Sneige, N ;

Buchholz, TA ;

Ross, MI ;

McNeese, MD ;

Buzdar, AU ;

Hortobagyi, GN ;

Singletary, SE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :460-469

← 1 2 3 4 5 →